Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Medifast, Inc.    MED


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Medifast, Inc. : Close to a key resistance level

11/20/2020 | 02:52am EST
11/20/2020 | 02:52am EST
long trade
Target price hit
Entry price : 172.63$ | Target : 200$ | Stop-loss : 153$ | Potential : 15.85%
Medifast, Inc. shares are trading close to a resistance zone which currently limits any upside potential. We expect that this level will be broken due to the stock's technical chart pattern.
Investors have an opportunity to buy the stock and target the $ 200.
Medifast, Inc. : Medifast, Inc. : Close to a key resistance level
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 95.62 USD

  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.

© Zonebourse.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 917 M - -
Net income 2020 103 M - -
Net cash 2020 165 M - -
P/E ratio 2020 22,4x
Yield 2020 2,33%
Capitalization 2 277 M 2 277 M -
EV / Sales 2020 2,30x
EV / Sales 2021 1,96x
Nbr of Employees 550
Free-Float 94,9%
Upcoming event on MEDIFAST, INC.
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 205,00 $
Last Close Price 194,35 $
Spread / Highest target 28,6%
Spread / Average Target 5,48%
Spread / Lowest Target -17,7%
EPS Revisions
Daniel R. Chard Chief Executive Officer & Director
Michael C. MacDonald Non-Executive Chairman
James P. Maloney Chief Financial Officer
William Baker Executive Vice President-Information Technology
Kevin G. Byrnes Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDIFAST, INC.77.36%2 277
BY-HEALTH CO., LTD.55.19%6 079
BIOGAIA AB (PUBL)9.78%1 104